RIPK1 and osteosarcoma: Li et al. demonstrated that the nano-drug delivery system modified by polypeptide nanomaterials could kill osteosarcoma cells in vitro by inducing RIP1- and RIP3-dependent necroptosis (Li et al., 2018).